Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia

AUTOR(ES)

Almeida, Maria Helena de, Fogliatto, Laura, Couto, Dulce

FONTE

Rev. Bras. Hematol. Hemoter.

DATA DE PUBLICAÇÃO

2014-01

RESUMO

Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.

Documentos Relacionados

• Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
• A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.
• Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
• Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
• The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.